Critical Reviews in Oncology / Hematology
Volume 78, Issue 2 , Pages 150-161 , May 2011

Serum CD44 levels predict survival in patients with low-risk myelodysplastic syndromes

  • J. Loeffler-Ragg

      Affiliations

    • Department of Internal Medicine I, Innsbruck Medical University, Innsbruck, Austria
    • ,
  • U. Germing

      Affiliations

    • Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany
    • ,
  • W.R. Sperr

      Affiliations

    • Department of Internal Medicine I, Division of Hematology and Hemostaseology, Vienna Medical University, Vienna, Austria
    • ,
  • H. Herrmann

      Affiliations

    • Ludwig Boltzmann Cluster Oncology, Vienna, Austria
    • ,
  • H. Zwierzina

      Affiliations

    • Department of Internal Medicine I, Innsbruck Medical University, Innsbruck, Austria
    • ,
  • P. Valent

      Affiliations

    • Department of Internal Medicine I, Division of Hematology and Hemostaseology, Vienna Medical University, Vienna, Austria
    • Ludwig Boltzmann Cluster Oncology, Vienna, Austria
    • ,
  • H. Ulmer

      Affiliations

    • Department of Biostatistics and Documentation, Innsbruck Medical University, Innsbruck, Austria
    • ,
  • R. Stauder

      Affiliations

    • Department of Internal Medicine V (Hematology and Oncology), Innsbruck Medical University, Anichstrasse 35, A-6020 Innsbruck, Austria
    • Corresponding Author InformationCorresponding author. Tel.: +43 512 504 23255.

,Accepted 28 May 2010.

References 

  1. Valent P, Hofmann W, Büsche G, et al. Meeting report: Vienna 2008 workshop of the German–Austrian working group for studying prognostic factors in myelodysplastic syndromes. Ann Hematol. 2009;
  2. Nimer S. Myelodysplastic syndromes. Blood. 2008;111(10):4841–4851
  3. Valent P, Horny H, Bennett J, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res. 2007;31(6):727–736
  4. Bennett J, Komrokji R. The myelodysplastic syndromes: diagnosis, molecular biology and risk assessment. Hematology. 2005;10(Suppl. 1):258–269
  5. Stauder R, Nösslinger T, Pfeilstöcker M, et al. Impact of age and comorbidity in myelodysplastic syndromes. J Natl Compr Cancer Netw. 2008;6(9):927–934
  6. Greenberg P, Cox C, LeBeau M, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079–2088
  7. Germing U, Hildebrandt B, Pfeilstöcker M, et al. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia. 2005;19(12):2223–2231
  8. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25(23):3503–3510
  9. Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007;110(13):4385–4395
  10. Sperr W, Wimazal F, Kundi M, et al. Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group. Ann Oncol. 2010;21(1):114–119
  11. Garcia-Manero G, Shan J, Faderl S, et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia. 2008;22(3):538–543
  12. Prosper F, Verfaillie C. Regulation of hematopoiesis through adhesion receptors. J Leukoc Biol. 2001;69(3):307–316
  13. Naor D, Sionov R, Ish-Shalom D. CD44: structure, function, and association with the malignant process. Adv Cancer Res. 1997;71:241–319
  14. Miyake K, Medina K, Hayashi S, Ono S, Hamaoka T, Kincade P. Monoclonal antibodies to Pgp-1/CD44 block lympho-hemopoiesis in long-term bone marrow cultures. J Exp Med. 1990;171(2):477–488
  15. Ghaffari S, Dougherty G, Lansdorp P, Eaves A, Eaves C. Differentiation-associated changes in CD44 isoform expression during normal hematopoiesis and their alteration in chronic myeloid leukemia. Blood. 1995;86(8):2976–2985
  16. Kansas G, Muirhead M, Dailey M. Expression of the CD11/CD18, leukocyte adhesion molecule 1, and CD44 adhesion molecules during normal myeloid and erythroid differentiation in humans. Blood. 1990;76(12):2483–2492
  17. Kansas G, Dailey M. Expression of adhesion structures during B cell development in man. J Immunol. 1989;142(9):3058–3062
  18. Legras S, Günthert U, Stauder R, et al. A strong expression of CD44-6v correlates with shorter survival of patients with acute myeloid leukemia. Blood. 1998;91(9):3401–3413
  19. Yokota A, Ishii G, Sugaya Y, Nishimura M, Saito Y, Harigaya K. Expression of exon v6-containing CD44 isoforms is related to poor prognosis of acute myelocytic leukemia. Hematol Oncol. 1998;16(4):131–141
  20. Stauder R, Eisterer W, Thaler J, Günthert U. CD44 variant isoforms in non-Hodgkin's lymphoma: a new independent prognostic factor. Blood. 1995;85(10):2885–2899
  21. Eisterer W, Bechter O, Söderberg O, et al. Elevated levels of soluble CD44 are associated with advanced disease and in vitro proliferation of neoplastic lymphocytes in B-cell chronic lymphocytic leukaemia. Leuk Res. 2004;28(10):1043–1051
  22. Stauder R, Van Driel M, Schwärzler C, et al. Different CD44 splicing patterns define prognostic subgroups in multiple myeloma. Blood. 1996;88(8):3101–3108
  23. Karmon Y, Manaster J, Chezar J. Immunophenotypic characterization of myelopoiesis in early and late myelodysplastic syndromes: use of CD44 as an aid in early diagnosis. Cytometry. 2002;50(4):225–230
  24. Nakamura H, Suenaga N, Taniwaki K, et al. Constitutive and induced CD44 shedding by ADAM-like proteases and membrane-type 1 matrix metalloproteinase. Cancer Res. 2004;64(3):876–882
  25. Cichy J, Kulig P, Puré E. Regulation of the release and function of tumor cell-derived soluble CD44. Biochim Biophys Acta. 2005;1745(1):59–64
  26. Nagano O, Saya H. Mechanism and biological significance of CD44 cleavage. Cancer Sci. 2004;95(12):930–935
  27. Okamoto I, Tsuiki H, Kenyon L, et al. Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors. Am J Pathol. 2002;160(2):441–447
  28. Cichy J, Puré E. Cytokines regulate the affinity of soluble CD44 for hyaluronan. FEBS Lett. 2004;556(1–3):69–74
  29. Stamenkovic I, Yu Q. Shedding light on proteolytic cleavage of CD44: the responsible sheddase and functional significance of shedding. J Invest Dermatol. 2009;129(6):1321–1324
  30. Nasu H, Hibi N, Ohyashiki J, et al. Serum soluble CD44 levels for monitoring disease states in acute leukemia and myelodysplastic syndromes. Int J Oncol. 1998;13(3):525–530
  31. Loeffler-Ragg J, Steurer M, Ulmer H, et al. Elevated levels of serum CD44 and E-cadherin predict an unfavourable outcome in myelodysplastic syndromes. Leukemia. 2006;20(11):2064–2067
  32. Bennett J, Catovsky D, Daniel M, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51(2):189–199
  33. Mayer S, zur Hausen A, Watermann D, et al. Increased soluble CD44 concentrations are associated with larger tumor size and lymph node metastasis in breast cancer patients. J Cancer Res Clin Oncol. 2008;134(11):1229–1235
  34. Naor D, Wallach-Dayan S, Zahalka M, Sionov R. Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Semin Cancer Biol. 2008;18(4):260–267
  35. Christofori G. Changing neighbours, changing behaviour: cell adhesion molecule-mediated signalling during tumour progression. EMBO J. 2003;22(10):2318–2323
  36. Amirghofran Z, Jalali S, Hosseini S, Vasei M, Sabayan B, Ghaderi A. Evaluation of CD44 and CD44v6 in colorectal carcinoma patients: soluble forms in relation to tumor tissue expression and metastasis. J Gastrointest Cancer. 2008;39(1–4):73–78
  37. Kawano T, Yanoma S, Nakamura Y, et al. Soluble CD44 standard, CD44 variant 5 and CD44 variant 6 and their relation to staging in head and neck cancer. Acta Otolaryngol. 2005;125(4):392–397
  38. Kopp R, Classen S, Wolf H, Gholam P, Possinger K, Wilmanns W. Predictive relevance of soluble CD44v6 serum levels for the responsiveness to second line hormone- or chemotherapy in patients with metastatic breast cancer. Anticancer Res. 2001;21(4B):2995–3000
  39. Takeuchi M, Tanizawa A, Fukumoto Y, Kikawa Y, Mayumi M. Serum soluble CD44 in pediatric patients with acute leukemia. J Pediatr Hematol Oncol. 1999;21(5):384–388
  40. Moreno C, Epuñan M, Minguell J. Expression of transmembrane and soluble forms of CD44H in human myeloid cell lines and its regulation by hyaluronic acid. Haematologica. 2000;85(3):321–322
  41. Anderegg U, Eichenberg T, Parthaune T, et al. ADAM10 is the constitutive functional sheddase of CD44 in human melanoma cells. J Invest Dermatol. 2008;
  42. Subramaniam V, Gardner H, Jothy S. Soluble CD44 secretion contributes to the acquisition of aggressive tumor phenotype in human colon cancer cells. Exp Mol Pathol. 2007;83(3):341–346
  43. Charrad R, Gadhoum Z, Qi J, et al. Effects of anti-CD44 monoclonal antibodies on differentiation and apoptosis of human myeloid leukemia cell lines. Blood. 2002;99(1):290–299
  44. Gadhoum Z, Delaunay J, Maquarre E, et al. The effect of anti-CD44 monoclonal antibodies on differentiation and proliferation of human acute myeloid leukemia cells. Leuk Lymphoma. 2004;45(8):1501–1510
  45. Jin L, Hope K, Zhai Q, Smadja-Joffe F, Dick J. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med. 2006;12(10):1167–1174
  46. Riechelmann H, Sauter A, Golze W, et al. Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. Oral Oncol. 2008;44(9):823–829
  47. Marangoni E, Lecomte N, Durand L, et al. CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts. Br J Cancer. 2009;100(6):918–922
  48. Malcovati L, Nimer S. Myelodysplastic syndromes: diagnosis and staging. Cancer Control. 2008;15(Suppl. 4):4–13

PII: S1040-8428(10)00140-X

doi: 10.1016/j.critrevonc.2010.05.008

Critical Reviews in Oncology / Hematology
Volume 78, Issue 2 , Pages 150-161 , May 2011

Article Tools

* Image Usage & Resolution